Phase Ib/II Open-Label, Randomized Evaluation of Second- or Third-Line (2L/3L) Atezolizumab (atezo) Plus Entinostat (entino) in MORPHEUS-HR Plus Breast Cancer (M-HR Plus BC)
ANNALS OF ONCOLOGY(2021)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
ANNALS OF ONCOLOGY(2021)